| scholarly article | Q13442814 |
| P50 | author | Alexandra Shillingburg | Q56958231 |
| P2093 | author name string | Mehdi Hamadani | |
| Sijin Wen | |||
| Jin Luo | |||
| Kathy Watkins | |||
| Aaron Cumpston | |||
| Abraham S Kanate | |||
| Michael Craig | |||
| Sonia Leadmon | |||
| Lauren Veltri | |||
| P2860 | cites work | Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics | Q83861540 |
| Efficacy and cost-benefit analysis of risk-adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization | Q84317235 | ||
| Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation | Q84931074 | ||
| Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data | Q33543723 | ||
| Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy | Q33861711 | ||
| Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma | Q34038564 | ||
| Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia | Q34229807 | ||
| Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma | Q34288599 | ||
| Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. | Q34490998 | ||
| Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial | Q34524632 | ||
| Economic evaluation of plerixafor for stem cell mobilization | Q36831799 | ||
| The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). | Q37375167 | ||
| Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept | Q37943423 | ||
| Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation | Q38210890 | ||
| Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas | Q38267567 | ||
| The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34(+) cells | Q39049318 | ||
| Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma | Q40201943 | ||
| Cost and Clinical Analysis of Autologous Hematopoietic Stem Cell Mobilization with G-CSF and Plerixafor Compared to G-CSF and Cyclophosphamide | Q40349501 | ||
| Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization | Q42133489 | ||
| Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantatio | Q43282877 | ||
| Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization. | Q44256421 | ||
| Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization | Q44433507 | ||
| Salvage bone marrow harvest in patients failing plerixafor-based stem cell mobilization attempt: feasibility and autologous transplantation outcomes | Q44985021 | ||
| Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma | Q46052750 | ||
| Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. | Q46793597 | ||
| Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation | Q47839930 | ||
| Predictive factors for poor peripheral blood stem cell mobilization and peak CD34(+) cell count to guide pre-emptive or immediate rescue mobilization. | Q47841093 | ||
| Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma | Q47913355 | ||
| Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure. | Q51385709 | ||
| Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. | Q51518039 | ||
| Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. | Q51705517 | ||
| Bone Marrow Transplantation: Prognostic Factors of Peripheral Blood Stem Cell Mobilization with Cyclophosphamide and Filgrastim (r-metHuG-CSF): The CD34+ Cell Dose Positively Affects the Time to Hematopoietic Recovery and Supportive Requirements afte | Q59312604 | ||
| Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategies | Q60976554 | ||
| A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome | Q71123629 | ||
| The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering | Q71558484 | ||
| Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma | Q74360817 | ||
| Peripheral blood CD34+ cell enumeration as a predictor of apheresis yield: an analysis of more than 1,000 collections | Q83194023 | ||
| Plerixafor | Q83265740 | ||
| P433 | issue | 12 | |
| P304 | page(s) | 1785-1792 | |
| P577 | publication date | 2015-10-13 | |
| P1433 | published in | Cytotherapy | Q5201399 |
| P1476 | title | Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use. | |
| P478 | volume | 17 |
| Q37738995 | A single center's experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation |
| Q90390561 | Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor |
| Q49887823 | Autologous hematopoietic progenitor cell mobilization and collection in adult patients presenting with multiple myeloma and lymphoma: A position-statement from the Turkish Society of Apheresis (TSA). |
| Q47447522 | Current practice of autologous hematopoietic progenitor cell mobilization in adult patients with multiple myeloma and lymphoma: The results of a survey from Turkish hematology research and education group (ThREG). |
| Q47914097 | Current strategies for the management of autologous peripheral blood stem cell mobilization failures in patients with multiple myeloma. |
| Q38658893 | Hematopoietic stem cell mobilization: current status and future perspective |
| Q38978669 | How do we mobilize and collect autologous peripheral blood stem cells? |
| Q49887745 | Management of mobilization failure in 2017. |
| Q38418369 | Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean mul |
| Q47325720 | Rapid prediction of stem cell mobilization using volume and conductivity data from automated hematology analyzers |
| Q54582789 | Successful peripheral blood stem cell mobilization with a cost-efficient single fixed-dose plerixafor schedule in poor mobilizers. |
Search more.